The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 30, 2015
Filed:
Jun. 27, 2013
Genentech, Inc., South San Francisco, CA (US);
Abbvie Inc., North Chicago, IL (US);
The Walter and Eliza Hall Institute of Medical Research, Parkville, AU;
Jonathan Bayldon Baell, Bundoora, AU;
Chinh Thien Bui, Balwyn North, AU;
Peter Colman, East Melbourne, AU;
Danette A. Dudley, Pacifica, CA (US);
Wayne J. Fairbrother, Burlingame, CA (US);
John A. Flygare, Burlingame, CA (US);
Guillaume Laurent Lessene, Bundoora, AU;
Chudi Ndubaku, Thomastown, AU;
George Nikolakopoulos, Thomastown, AU;
Carl Steven Rye, Epsom, CA (US);
Brad Edmund Sleebs, Reservoir, AU;
Brian John Smith, Sunbury, AU;
Keith Geoffrey Watson, Surry Hills, AU;
Steven W. Elmore, Northbrook, IL (US);
Andrew M. Petros, Mundelein, IL (US);
Andrew J. Souers, Evanston, IL (US);
Peter Czabotar, Melbourne, AU;
AbbVie Inc., North Chicago, IL (US);
Genentech, Inc., South San Francisco, CA (US);
The Walter and Eliza Hall Institute of Medical Research, Victoria, AU;
Abstract
In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.